BE2017C002I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C002I2
BE2017C002I2 BE2017C002C BE2017C002C BE2017C002I2 BE 2017C002 I2 BE2017C002 I2 BE 2017C002I2 BE 2017C002 C BE2017C002 C BE 2017C002C BE 2017C002 C BE2017C002 C BE 2017C002C BE 2017C002 I2 BE2017C002 I2 BE 2017C002I2
Authority
BE
Belgium
Application number
BE2017C002C
Other languages
French (fr)
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C002(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp filed Critical Icos Corp
Publication of BE2017C002I2 publication Critical patent/BE2017C002I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
BE2017C002C 2004-05-13 2017-02-16 BE2017C002I2 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57078404P 2004-05-13 2004-05-13

Publications (1)

Publication Number Publication Date
BE2017C002I2 true BE2017C002I2 (enExample) 2024-08-08

Family

ID=34969603

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C002C BE2017C002I2 (enExample) 2004-05-13 2017-02-16

Country Status (23)

Country Link
US (14) USRE44638E1 (enExample)
EP (4) EP3943494A1 (enExample)
JP (1) JP2007537291A (enExample)
CN (2) CN102229609A (enExample)
AU (2) AU2005245875C1 (enExample)
BE (1) BE2017C002I2 (enExample)
CA (1) CA2566609C (enExample)
CY (3) CY2016046I1 (enExample)
DK (2) DK1761540T3 (enExample)
ES (3) ES2605792T3 (enExample)
FR (1) FR17C1007I2 (enExample)
HR (2) HRP20161751T1 (enExample)
HU (3) HUE030950T2 (enExample)
IL (4) IL179176A (enExample)
LT (3) LT2612862T (enExample)
LU (1) LUC00005I2 (enExample)
ME (2) ME02688B (enExample)
NL (1) NL300867I2 (enExample)
PL (3) PL3153514T3 (enExample)
PT (3) PT1761540T (enExample)
RS (2) RS55551B1 (enExample)
SI (2) SI3153514T1 (enExample)
WO (2) WO2005113556A1 (enExample)

Families Citing this family (417)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
ES2605792T3 (es) * 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
CA2730540A1 (en) * 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2006068760A2 (en) * 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
AU2006214190A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
WO2008127226A2 (en) * 2006-04-04 2008-10-23 The Regents Of The University Of California P13 kinase antagonists
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2009002553A1 (en) * 2007-06-25 2008-12-31 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
FR2918668B1 (fr) * 2007-07-09 2009-08-21 Arkema France Procede ameliore de preparation d'alcoxyamines issues de nitroxydes beta-phosphores.
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US20110021541A1 (en) * 2007-11-13 2011-01-27 White Stephen L Inhibitors of human phosphatidyl-inositol 3-kinase delta
AU2014203687B2 (en) * 2008-01-04 2016-04-14 Intellikine Llc Certain chemical entities, compositions and methods
RU2513636C2 (ru) * 2008-01-04 2014-04-20 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN104926815B (zh) * 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
EP2277881A4 (en) * 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2313414B1 (en) 2008-07-08 2015-11-04 Intellikine, LLC Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
ES2597903T3 (es) * 2008-07-29 2017-01-24 Boehringer Ingelheim International Gmbh 5-Alquinil-pirimidinas
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
SG10201703911XA (en) * 2008-11-13 2017-06-29 Gilead Calistoga Llc Therapies for hematologic malignancies
RU2011137399A (ru) 2009-02-12 2013-03-20 Астеллас Фарма Инк. Гетероциклическое производное
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
CA2759724A1 (en) * 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
DK2467141T3 (en) 2009-08-17 2019-02-18 Intellikine Llc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
CN102625708A (zh) * 2009-09-09 2012-08-01 阿维拉制药公司 Pi3激酶抑制剂及其用途
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
GB0918249D0 (en) * 2009-10-19 2009-12-02 Respivert Ltd Compounds
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2011163195A1 (en) * 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2593455B1 (en) 2010-07-14 2015-03-18 F.Hoffmann-La Roche Ag Purine compounds selective for i3 p110 delta, and methods of use
JP5765342B2 (ja) 2010-08-10 2015-08-19 アステラス製薬株式会社 へテロ環化合物
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JP2013545749A (ja) * 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CN102719517B (zh) * 2011-03-29 2015-08-19 中国科学院上海药物研究所 一种检测化合物对人Ⅰ型PI3Ks抑制活性的方法
CN103702989B (zh) 2011-05-04 2017-07-07 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
CN102838601A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
CN102838600A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
HK1198475A1 (en) 2011-07-19 2015-05-08 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
PH12014500547A1 (en) 2011-10-03 2014-04-21 Respivert Ltd 1-pyrazolyl-3-(-4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
WO2013082540A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
PL2790705T3 (pl) 2011-12-15 2018-06-29 Novartis Ag Zastosowanie inhibitorów czynności lub funkcji PI3K
AU2015252058A1 (en) * 2012-03-05 2015-11-19 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
CN106146506A (zh) * 2012-03-05 2016-11-23 吉利德卡利斯托加公司 (s)‑2‑(1‑(9h‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3h)‑酮的多晶型物
KR20140141596A (ko) * 2012-03-13 2014-12-10 레스피버트 리미티드 결정질 pi3 키나아제 저해제
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014023083A1 (zh) * 2012-08-08 2014-02-13 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
CA2882134A1 (en) * 2012-08-14 2014-02-20 Gilead Calistoga Llc Combination therapies for treating cancer
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
AP2015008328A0 (en) * 2012-10-16 2015-03-31 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
EP2920172B1 (en) 2012-11-16 2019-12-25 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA2895785A1 (en) 2012-12-21 2014-06-26 Jerry Evarts Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
NZ708864A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
CN105263899B (zh) * 2013-01-21 2017-11-14 国立大学法人大阪大学 苯氧基烷基胺化合物
WO2014128612A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JO3279B1 (ar) * 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
TR201806822T4 (tr) 2013-06-14 2018-06-21 Gilead Calistoga Llc Fosfatidilinositol 3-kinaz inhibitörleri.
UY35675A (es) * 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN104736538B (zh) * 2013-08-01 2016-09-21 杭州普晒医药科技有限公司 一种抑制剂的晶型及其制备方法和用途
CN104418858B (zh) 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
KR20160058889A (ko) 2013-09-22 2016-05-25 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092810A2 (en) 2013-11-20 2015-06-25 Cadila Healthcare Limited Amorphous form of idelalisib
AU2014354769A1 (en) * 2013-11-26 2016-05-26 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
BR112016012794A2 (pt) 2013-12-05 2017-08-08 Acerta Pharma Bv Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) * 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
EP3094332B1 (en) * 2014-01-15 2018-09-12 The Trustees of Columbia University in the City of New York Carbonyl erastin analogs and their use
WO2015109286A1 (en) 2014-01-20 2015-07-23 Gilead Sciences, Inc. Therapies for treating cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2921874T3 (es) 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MX2016016538A (es) * 2014-06-13 2017-05-01 Gilead Sciences Inc Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
EA201692249A1 (ru) 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
KR20170010063A (ko) * 2014-06-13 2017-01-25 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
JP6230205B2 (ja) 2014-06-19 2017-11-15 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
CN104130261B (zh) * 2014-08-04 2016-03-02 山东康美乐医药科技有限公司 艾德利布的合成方法
PL3179992T3 (pl) 2014-08-11 2022-08-16 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
CN104262344B (zh) * 2014-08-22 2015-11-04 苏州明锐医药科技有限公司 艾德拉尼的制备方法
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
CN105503877A (zh) 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
WO2016049211A1 (en) 2014-09-26 2016-03-31 Gilead Sciences, Inc. Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
CA2966252C (en) 2014-11-01 2023-10-24 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Phosphoinositide 3-kinase inhibitors
ES2685252T3 (es) 2014-12-09 2018-10-08 Ratiopharm Gmbh Sal de idelalisib
EP3048104A1 (en) 2015-01-20 2016-07-27 Sandoz AG Amorphous and crystalline forms of idelalisib and process for forming the same
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
WO2016108206A2 (en) * 2014-12-31 2016-07-07 Dr. Reddy’S Laboratories Limited Processes for preparation of idelalisib and intermediates thereof
KR101710461B1 (ko) * 2015-01-16 2017-02-27 순천향대학교 산학협력단 키랄 2-플루오로-4-나이트로 부탄산 유도체의 제조방법
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3831833B1 (en) 2015-02-27 2022-10-26 Incyte Holdings Corporation Processes for the preparation of a pi3k inhibitor
MY199989A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US20180064714A1 (en) * 2015-03-13 2018-03-08 Mylan Laboratories Ltd Process for the Preparation of Amorphous Idelalisib and its Premix
WO2016156240A1 (en) 2015-03-31 2016-10-06 Synthon B.V. Improved process for preparing idelalisib
WO2016157136A1 (en) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Crystalline forms of idelalisib
CN106146502B (zh) * 2015-04-09 2019-01-04 上海医药工业研究院 艾代拉里斯的合成方法及制备中间体
CN108033961A (zh) 2015-04-15 2018-05-15 上海方楠生物科技有限公司 一种艾德力布的无定型物及其制备方法
CN106146411A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 (s)-2-(1-氨基-丙基)-5-氟-3-苯基-3h-喹唑啉-4-酮的制备方法
CN106146503A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 一种Idelalisib的制备方法
CN106146352A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 Idelalisib中间体及其制备方法
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CZ2015347A3 (cs) 2015-05-22 2016-11-30 Zentiva, K.S. Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava
CN106279171A (zh) * 2015-06-09 2017-01-04 南京安源生物医药科技有限公司 一种Idelalisib的制备方法
WO2016209961A1 (en) 2015-06-23 2016-12-29 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
SI3317284T1 (sl) 2015-07-02 2020-02-28 F. Hoffmann-La Roche Ag Spojine benzoksazepin oksazolidinona in načini uporabe
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
CZ2015575A3 (cs) * 2015-08-26 2017-03-08 Zentiva, K.S. Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
EP3344624B8 (en) 2015-09-02 2023-11-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
LT3364958T (lt) 2015-10-23 2023-06-12 Navitor Pharmaceuticals, Inc. Sestrin-gator2 sąveikos moduliatoriai ir jų panaudojimas
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US10857156B2 (en) 2015-11-20 2020-12-08 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
HU231016B1 (hu) * 2015-11-30 2019-11-28 Egis Gyógyszergyár Zrt. Idelalisib új polimorf és szolvát formája
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
KR20180094976A (ko) 2015-12-17 2018-08-24 길리애드 사이언시즈, 인코포레이티드 Tank-결합 키나제 억제제 화합물
WO2019051063A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
WO2017130221A1 (en) * 2016-01-29 2017-08-03 Sun Pharmaceutical Industries Limited Improved process for the preparation of idelalisib
US20190040066A1 (en) 2016-02-03 2019-02-07 Lupin Limited Process for the preparation of phosphatidylinositol 3-kinase inhibitor
CN107033145B (zh) * 2016-02-04 2019-11-22 浙江大学 苯并噻嗪和苯并噻二嗪类化合物及制备和应用
AU2017228371A1 (en) 2016-03-04 2018-09-13 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
PL3426244T3 (pl) 2016-03-09 2023-09-25 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
HUE055197T2 (hu) 2016-03-09 2021-11-29 Raze Therapeutics Inc 3-Foszfoglicerát-dehidrogenáz inhibitorok és alkalmazásuk
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190079713A (ko) 2016-06-13 2019-07-05 아이-맵 항-pd-l1 항체 및 이것의 사용
CN106074430A (zh) * 2016-06-13 2016-11-09 佛山市腾瑞医药科技有限公司 一种艾代拉利司泡腾片及其制备方法
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2017221272A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Process for the preparation of idelalisib
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
KR101932146B1 (ko) * 2016-07-14 2018-12-24 주식회사 바이오웨이 Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
EP3272348A1 (en) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising idelalisib
US20180036289A1 (en) 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
ES2906581T3 (es) 2016-09-02 2022-04-19 Gilead Sciences Inc Compuestos moduladores de los receptores tipo Toll
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CA3039202A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN106632337B (zh) * 2016-10-18 2018-11-20 湖北生物医药产业技术研究院有限公司 艾代拉里斯的晶型、药物组合物、制备方法和用途
CA3040286A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
EP3538091A4 (en) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
US11730819B2 (en) 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
KR102156199B1 (ko) 2017-01-24 2020-09-17 아이-맵 바이오파마 유에스 리미티드 항-cd73 항체 및 이것의 사용
AR110998A1 (es) 2017-02-24 2019-05-22 Gilead Sciences Inc Inhibidores de la tirosina cinasa de bruton
WO2018156901A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
EP4338802A3 (en) 2017-03-08 2024-09-04 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US10870650B2 (en) 2017-04-24 2020-12-22 Natco Pharma Limited Process for the preparation of amorphous idelalisib
CN116370448B (zh) 2017-04-26 2026-01-13 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CU24606B1 (es) 2017-06-22 2022-06-06 Novartis Ag Moléculas de anticuerpo que se unen a cd73
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
RU2020108454A (ru) 2017-07-31 2021-09-02 Дзе Трастиз Оф Коламбия Юниверсити Ин Дзе Сити Оф Нью Йорк Соединения, композиции и способы лечения t-клеточного острого лимфобластного лейкоза
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
AU2018324037A1 (en) 2017-08-29 2020-04-16 Monash University Lymphatic system-directing lipid prodrugs
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CA3076613A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019092253A1 (en) 2017-11-10 2019-05-16 Synthon B.V. Process for preparing idelalisib
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11701361B2 (en) * 2018-01-05 2023-07-18 National Institutes Of Health (Nch), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
CN108409674A (zh) * 2018-02-09 2018-08-17 南京法恩化学有限公司 一种艾代拉利司中间体的制备方法
MX2020008404A (es) 2018-02-13 2020-09-25 Gilead Sciences Inc Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
EP3755725A1 (en) 2018-02-23 2020-12-30 BicycleTX Limited Multimeric bicyclic peptide ligands
SG11202008067QA (en) 2018-02-27 2020-09-29 Artax Biopharma Inc Chromene derivatives as inhibitors of tcr-nck interaction
CN108409740B (zh) * 2018-03-14 2020-05-08 盐城师范学院 一种艾代拉里斯制备方法
WO2019178596A1 (en) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
ES3035911T3 (en) 2018-04-19 2025-09-11 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
PL4043460T3 (pl) 2018-04-24 2024-10-28 Merck Patent Gmbh Związki przeciwproliferacyjne i ich zastosowania
TWI884914B (zh) 2018-04-24 2025-06-01 美商維泰克斯製藥公司 喋啶酮化合物及其用途
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
EP3814272A4 (en) 2018-05-11 2022-03-02 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
US10703733B2 (en) 2018-05-14 2020-07-07 Gilead Sciences, Inc. MCL-1 inhibitors
CN112513085B (zh) 2018-05-24 2024-06-18 詹森生物科技公司 Psma结合剂及其用途
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
RS65761B1 (sr) 2018-06-15 2024-08-30 Janssen Pharmaceutica Nv Analozi rapamicina i njihova upotreba
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20200077906A1 (en) 2018-09-07 2020-03-12 Augusta University Research Institute, Inc. Method and System for Monitoring Brain Function and Intracranial Pressure
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
JP2022512779A (ja) 2018-10-23 2022-02-07 バイスクルテクス・リミテッド 二環式ペプチドリガンドおよびその使用
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
US11053241B2 (en) 2018-11-30 2021-07-06 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
KR20250167680A (ko) 2018-11-30 2025-12-01 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CN109593066B (zh) * 2018-12-21 2020-06-19 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用
CN113348021B (zh) 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2020345962A1 (en) 2019-09-11 2022-03-31 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MY209360A (en) 2019-10-31 2025-07-03 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI870497B (zh) 2019-11-01 2025-01-21 美商奈維特製藥公司 使用mtorc1調節劑的治療方法
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
AU2020407200A1 (en) 2019-12-17 2022-07-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220151160A (ko) 2019-12-23 2022-11-14 카이메라 쎄라퓨틱스 인코포레이티드 Smarca 분해제 및 이의 용도
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
KR20210095495A (ko) * 2020-01-23 2021-08-02 주식회사 바이오웨이 신규한 퀴나졸리논 화합물 및 이를 포함하는 약학적 조성물
KR20220149534A (ko) 2020-02-05 2022-11-08 퓨어테크 엘와이티, 아이엔씨. 신경스테로이드의 지질 전구약물
KR20220142484A (ko) 2020-02-14 2022-10-21 조운스 테라퓨틱스, 인크. Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
CA3170411A1 (en) 2020-03-03 2021-09-10 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
EP4121043A4 (en) 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
CN113512042B (zh) * 2020-04-09 2024-06-11 成都赜灵生物医药科技有限公司 取代喹唑啉-4-酮类化合物及其制备方法和用途
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
JP2023525383A (ja) * 2020-05-16 2023-06-15 フォチョン・バイオサイエンシーズ・リミテッド キナーゼ阻害剤としての化合物
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
CN111840297B (zh) * 2020-08-24 2023-06-16 天津济坤医药科技有限公司 艾代拉里斯在制备用于治疗肝纤维化疾病的药物中的应用
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
JP2023553866A (ja) 2020-12-02 2023-12-26 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤、及びその使用
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3210246A1 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
MX2023009060A (es) 2021-02-02 2023-09-29 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
EP4291235A4 (en) 2021-02-12 2025-01-08 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
WO2022174269A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
IL307673A (en) 2021-04-16 2023-12-01 Ikena Oncology Inc MEK inhibitors and their use
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AR127505A1 (es) 2021-10-29 2024-01-31 Kymera Therapeutics Inc Degradadores irak-4 y síntesis de los mismos
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
MX2024011279A (es) 2022-03-17 2024-09-25 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos.
CA3254506A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH -2
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
CN117088867A (zh) * 2022-05-19 2023-11-21 杭州百诚医药科技股份有限公司 可吸入型芳环并噻嗪及类似物、含其的药物组合物及其在抗炎、抗肿瘤中的应用
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
KR20250057801A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AR131141A1 (es) 2022-11-22 2025-02-19 Pic Therapeutics Inc Inhibidores de eif4e y usos de los mismos
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
CN120379669A (zh) 2023-06-23 2025-07-25 凯麦拉医疗公司 Irak降解剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202529769A (zh) 2023-09-21 2025-08-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑及其用途
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35862A (en) * 1862-07-08 Improved portable evaporator for saccharine jutces
DE1249281B (enExample) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
NL7204972A (enExample) 1971-04-21 1972-10-24
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
JPS55118917A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118918A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6017375B2 (ja) 1979-06-20 1985-05-02 三菱電機株式会社 ポリアミド樹脂の製造方法
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS6310777A (ja) 1986-07-01 1988-01-18 Hokuriku Seiyaku Co Ltd ピペラジンアセトアミド誘導体
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
FI970588L (fi) 1994-08-12 1997-04-11 Pro Neuron Inc Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1997043276A1 (en) 1996-05-15 1997-11-20 Pfizer Inc. Novel 2,3 disubstituted-4(3h)-quinazolinones
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) * 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
UA64713C2 (uk) 1996-12-31 2004-03-15 Reddys Lab Ltd Dr Похідні азолідиндіону, спосіб їх одержання (варіанти), фармацевтичні композиції на їх основі, спосіб попередження або лікування, спосіб зниження рівня глюкози і проміжна сполука
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
IL130900A0 (en) 1997-02-28 2001-01-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
EP0884310B1 (en) 1997-06-09 2005-09-07 Pfizer Products Inc. Quinazolin-4-one ampa antagonists
AU8280798A (en) 1997-07-03 1999-01-25 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
WO1999034804A1 (en) 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation A2a adenosine receptor agonists
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
AUPQ136299A0 (en) 1999-07-02 1999-07-22 Microsystem Controls Pty Ltd Coin validation
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
CA2388646C (en) * 1999-10-27 2009-01-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
PT1268472E (pt) 2000-02-07 2005-01-31 Bristol Myers Squibb Co Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
IL152275A0 (en) 2000-04-25 2003-05-29 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6518227B2 (en) * 2001-02-13 2003-02-11 Robert Woosley Solvent composition for denture adhesive
AU2003247483A1 (en) 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
AU2003255528B2 (en) 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (en) 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
HRP20131159B1 (hr) 2002-09-30 2019-11-01 Bayer Ip Gmbh Taljeni azol-pirimidin derivati
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
BR0317572A (pt) 2002-12-20 2005-11-22 Warner Lambert Co Benzoxazinas e seus derivados como inibidores de pi3ks
EP1611119A1 (en) 2003-04-03 2006-01-04 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
BRPI0410913A (pt) 2003-06-05 2006-06-27 Warner Lambert Co benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
EP1636212B1 (en) 2003-06-05 2007-06-27 Warner-Lambert Company LLC Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
WO2004108708A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
JP2006526608A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
BRPI0411092A (pt) 2003-06-05 2006-07-18 Warner Lambert Co benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005067901A2 (en) * 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
CA2730540A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
CA2567883A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
JP5184887B2 (ja) 2004-09-09 2013-04-17 ナトコ ファーマ リミテッド ｂｃｒ−ａｂｌキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production
SG10201703911XA (en) * 2008-11-13 2017-06-29 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
ES2634492T3 (es) 2008-12-24 2017-09-28 Prana Biotechnology Ltd Compuestos de quinazolinona
CN102439012A (zh) * 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
JP2013504604A (ja) 2009-09-18 2013-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤としてのキナゾリノン誘導体
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CN106146506A (zh) 2012-03-05 2016-11-23 吉利德卡利斯托加公司 (s)‑2‑(1‑(9h‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3h)‑酮的多晶型物
WO2014023083A1 (zh) 2012-08-08 2014-02-13 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
EP3943494A1 (en) 2022-01-26
CY2016046I2 (el) 2017-11-14
CN102229609A (zh) 2011-11-02
US20130116266A1 (en) 2013-05-09
WO2005113554A2 (en) 2005-12-01
US8993583B2 (en) 2015-03-31
US8779131B2 (en) 2014-07-15
US8586597B2 (en) 2013-11-19
HRP20161657T1 (hr) 2017-02-10
PL3153514T3 (pl) 2022-01-10
EP3153514B1 (en) 2021-04-21
LT1761540T (lt) 2017-02-27
US20160075705A1 (en) 2016-03-17
IL269976B (en) 2021-04-29
USRE44599E1 (en) 2013-11-12
HUS1700006I1 (hu) 2017-03-28
IL241732B (en) 2019-10-31
SI2612862T1 (sl) 2017-04-26
CY1118493T1 (el) 2017-07-12
ME02688B (me) 2017-10-20
PT1761540T (pt) 2016-12-07
PL1761540T3 (pl) 2017-06-30
US20140121224A1 (en) 2014-05-01
CA2566609C (en) 2012-06-26
US20200017503A1 (en) 2020-01-16
SI3153514T1 (sl) 2022-02-28
FR17C1007I1 (fr) 2017-04-21
CY1118516T1 (el) 2017-07-12
EP2612862A2 (en) 2013-07-10
LTPA2017004I1 (lt) 2017-03-10
IL281945A (en) 2021-05-31
US20140378479A1 (en) 2014-12-25
PL2612862T3 (pl) 2017-08-31
US10906907B2 (en) 2021-02-02
IL179176A0 (en) 2007-03-08
JP2007537291A (ja) 2007-12-20
WO2005113554A3 (en) 2006-04-06
AU2005245875A1 (en) 2005-12-01
HUE030950T2 (en) 2017-06-28
DK1761540T3 (en) 2016-11-21
US20130231356A1 (en) 2013-09-05
EP2612862B1 (en) 2016-09-14
ES2873875T3 (es) 2021-11-04
US20210332047A1 (en) 2021-10-28
ME02695B (me) 2017-10-20
WO2005113556A1 (en) 2005-12-01
RS55546B1 (sr) 2017-05-31
AU2005245875B2 (en) 2009-07-30
LTC1761540I2 (lt) 2019-04-10
NL300867I2 (enExample) 2017-05-09
RS55551B1 (sr) 2017-05-31
PT2612862T (pt) 2016-12-15
CY2016046I1 (el) 2017-11-14
US20100256167A1 (en) 2010-10-07
AU2009230739A1 (en) 2009-11-12
CN101031569A (zh) 2007-09-05
ES2607804T3 (es) 2017-04-04
LUC00005I1 (enExample) 2017-02-21
US8980901B2 (en) 2015-03-17
EP1761540A1 (en) 2007-03-14
US20120015964A1 (en) 2012-01-19
EP1761540B1 (en) 2016-09-28
PT3153514T (pt) 2021-06-25
DK2612862T3 (en) 2016-12-05
CA2566609A1 (en) 2005-12-01
US8207153B2 (en) 2012-06-26
US7932260B2 (en) 2011-04-26
IL179176A (en) 2015-10-29
HUE030839T2 (en) 2017-06-28
US20080275067A1 (en) 2008-11-06
EP3153514A1 (en) 2017-04-12
EP2612862A3 (en) 2014-01-08
CN101031569B (zh) 2011-06-22
US20140121223A1 (en) 2014-05-01
HRP20161751T1 (hr) 2017-04-07
IL241732A0 (en) 2015-11-30
FR17C1007I2 (fr) 2018-03-23
AU2005245875C1 (en) 2017-08-31
US20100256168A1 (en) 2010-10-07
US9149477B2 (en) 2015-10-06
USRE44638E1 (en) 2013-12-10
LUC00005I2 (enExample) 2017-05-02
US10336756B2 (en) 2019-07-02
LT2612862T (lt) 2017-01-25
ES2605792T3 (es) 2017-03-16

Similar Documents

Publication Publication Date Title
BE2024C508I2 (enExample)
BE2023C542I2 (enExample)
BE2022C549I2 (enExample)
BE2021C001I2 (enExample)
BE2020C513I2 (enExample)
BE2020C517I2 (enExample)
BE2019C540I2 (enExample)
BE2019C523I2 (enExample)
BE2019C548I2 (enExample)
BE2019C506I2 (enExample)
BE2020C525I2 (enExample)
BE2017C027I2 (enExample)
BE2017C023I2 (enExample)
NL300867I2 (enExample)
BE2016C067I2 (enExample)
BE2016C014I2 (enExample)
BE2014C071I2 (enExample)
BE2014C064I2 (enExample)
BE2014C063I2 (enExample)
BE2014C010I2 (enExample)
BE2013C071I2 (enExample)
BE2013C021I2 (enExample)
BE2012C025I2 (enExample)
JP2004224337A5 (enExample)
DE502005010575D1 (enExample)